{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:51Z","timestamp":1792178991154,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1136\/ard-2023-224652","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:25:23Z","timestamp":1705083923000},"page":"826-829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Current myositis clinical trials and tribulations"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct05335278","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Didem","family":"Saygin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie J","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224652_bib1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224652_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cproderm study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2023-224652_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.26285","article-title":"Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development","volume":"91","author":"Paganoni","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1136\/ard-2023-224652_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13063-022-06312-x","article-title":"Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer","volume":"23","author":"Snowdon","year":"2022","journal-title":"Trials"},{"key":"10.1136\/ard-2023-224652_bib5","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar3704","article-title":"Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine","volume":"14","author":"Schiopu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224652_bib6","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/art.10358","article-title":"Differences in idiopathic inflammatory myopathy phenotypes and genotypes between mesoamerican mestizos and North American caucasians: ethnogeographic influences in the genetics and clinical expression of myositis","volume":"46","author":"Shamim","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224652_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-Pl7 and anti-Pl12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224652_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00296-019-04302-y","article-title":"Disability in idiopathic inflammatory myopathies: questionnaire-based study","volume":"39","author":"Opinc","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2023-224652_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer"},{"key":"10.1136\/ard-2023-224652_bib10","unstructured":"Administration USDoHaHSFaD. Decentralized clinical trials for drugs, biological products, and devices guidance for industry, investigators, and other stakeholders. Maryland FDA; 2023."},{"key":"10.1136\/ard-2023-224652_bib11","unstructured":"Initiative CTT. Decentralized clinical trials; 2018."},{"key":"10.1136\/ard-2023-224652_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3899\/jrheum.131247","article-title":"Patient-reported outcomes and adult patients\u2019 disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group","volume":"41","author":"Alexanderson","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224652_bib13","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3899\/jrheum.161252","article-title":"Advancing the development of patient-reported outcomes for adult myositis at OMERACT 2016: an International Delphi study","volume":"44","author":"Park","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224652_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3899\/jrheum.141243","article-title":"Patients\u2019 experience of Myositis and further validation of a myositis-specific patient reported outcome measure - establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12","volume":"42","author":"Regardt","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224652_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.semarthrit.2020.06.006","article-title":"Assessing the content validity of patient-reported outcome measures in adult myositis: a report from the OMERACT myositis working group","volume":"50","author":"Esfandiary","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224652_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152111","article-title":"Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: international study from the OMERACT myositis working group","volume":"58","author":"DiRenzo","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224652_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-224652_bib18","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224652_bib19","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224652_bib20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224652_bib21","series-title":"Efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis","first-page":"106","author":"Werth","year":"2022"},{"key":"10.1136\/ard-2023-224652_bib22","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard-2023-224652_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-224652_bib24","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:02:01Z","timestamp":1736056921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0003496724000803"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224652","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current myositis clinical trials and tribulations","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}